Randomized Trial of IN.PACT Admiral® Drug Coated Balloon vs Standard PTA for the Treatment of SFA and Proximal Popliteal Arterial Disease (INPACT SFA I)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Medtronic Endovascular
ClinicalTrials.gov Identifier:
First received: August 3, 2010
Last updated: September 3, 2015
Last verified: July 2015
The objective of this Study is to evaluate the safety and efficacy of the IN.PACT Admiral® drug coated PTA balloon, utilized for the dilatation of the narrowed sections of the artery, as compared to other standard (non drug coated) PTA balloons. The IN.PACT Admiral, besides the mechanical dilatation effect typical of all PTA balloons, releases a drug (paclitaxel) from the balloon surface into the vessel walls. This drug absorption is intended to limit the chances and the entity of artery re-narrowing over time.

Condition Intervention
Peripheral Arterial Disease (PAD)
Device: Drug-Coated Balloon (DCB)
Device: PTA Balloon: Balloon Angioplasty

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Randomized Trial of IN.PACT Admiral(TM) Drug Coated Balloon vs Standard PTA for the Treatment of SFA and Proximal Popliteal Arterial Disease

Resource links provided by NLM:

Further study details as provided by Medtronic Endovascular:

Primary Outcome Measures:
  • Primary Patency [ Time Frame: 12 Month ] [ Designated as safety issue: No ]
    Primary patency is defined as freedom from clinically-driven target lesion revascularization (TLR) or restenosis as determined by duplex ultrasound (DUS) Peak Systolic Velocity Ratio (PSVR) ≤ 2.4.

  • Primary Safety Composite [ Time Frame: 12 month ] [ Designated as safety issue: Yes ]
    Primary safety composite is defined as freedom from death through 30 days or target limb major amputation or clinically-driven target vessel revascularization (CD-TVR) within 12 months post index procedure.

Secondary Outcome Measures:
  • Major Adverse Events (MAE) Composite [ Time Frame: 12 month ] [ Designated as safety issue: Yes ]
    Major Adverse Events (MAE) composite defined as all-cause death, clinically-driven target vessel revascularization (CD-TVR), major target limb amputation, thrombosis at the target lesion site

  • All-cause Death [ Time Frame: 12 month ] [ Designated as safety issue: Yes ]
  • Target Vessel Revascularization (TVR) [ Time Frame: 12 month ] [ Designated as safety issue: Yes ]
  • Target Lesion Revascularization (TLR) [ Time Frame: 12 month ] [ Designated as safety issue: Yes ]
  • Time to First Clinically Driven Target Lesion Revascularization (CD-TLR) [ Time Frame: 12 month ] [ Designated as safety issue: No ]
    Clinically-driven target lesion revascularization (CD-TLR) is defined as any re-intervention within the target lesion due to symptoms or drop of ankle brachial index (ABI) of ≥20% or >0.15 when compared to post-procedure baseline.

  • Major Target Limb Amputation [ Time Frame: 12 month ] [ Designated as safety issue: Yes ]
  • Thrombosis at the Target Lesion [ Time Frame: 12 month ] [ Designated as safety issue: Yes ]
  • Primary Sustained Clinical Improvement [ Time Frame: 12 month ] [ Designated as safety issue: No ]
    Freedom from target limb amputation, target vessel revascularization (TVR), and increase in Rutherford class. Rutherford classification is a clinical staging system that is used to describe peripheral arterial disease.

  • Secondary Sustained Clinical Improvement [ Time Frame: 12 month ] [ Designated as safety issue: No ]
    Freedom from target limb amputation and increase in Rutherford class.

  • Duplex-defined Binary Restenosis (Peak Systolic Velocity Ratio (PSVR) >2.4). [ Time Frame: 12 month ] [ Designated as safety issue: No ]
    Duplex ultrasound measurement that measures the peak systolic velocity of blood (cm/sec) within a lesion divided by the peak velocity of blood (cm/sec) proximal to the lesion.

  • Duplex-defined Binary Restenosis (Peak Systolic Velocity Ratio >3.4). [ Time Frame: 12 month ] [ Designated as safety issue: No ]
  • Change From Baseline in Quality of Life Assessment by EuroQol Group 5-Dimension Self Report Questionnaire (EQ5D) at Month 12 [ Time Frame: Baseline to 12 month ] [ Designated as safety issue: No ]

    Quality of life assessment by EQ5D at 1 year compared to baseline. EQ5D is a standardised measure of health status and economic appraisal. The EQ5D consists of the EQ5D descriptive system which comprises the following variables for the 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: (1) no problems, (2) some problems, (3) extreme problems. A complex algorithm that took individual dimensions and generated an overall score was used.

    EQ5D health state is used in the algorithm to calculate an overall score where - 0.109 = 'worst possible outcome' and 1.000 = 'best possible outcome'.

  • Change From Baseline in Walking Capacity Assessment by Walking Impairment Questionnaire (WIQ) at 12 Months [ Time Frame: 12 month ] [ Designated as safety issue: No ]

    Walking capacity assessment by WIQ at 1 year compared to baseline. WIQ is a quality of life questionnaire that was specifically designed to assess the degree of impairment experienced by patients with claudication.

    Clinical outcomes were assessed by patients responses to question 1A. Question 1A is specific for calf or buttocks claudication and is used to create a summary score for analysis. Question 1A is expressed on a scale of 0% (unable to perform because of severe claudication) to 100% (no impairment).

  • Device Success [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
    Device success is defined as successful delivery, balloon inflation and deflation and retrieval of the intact study device without burst below rated burst pressure (RBP).

  • Procedural Success [ Time Frame: Day 1 ] [ Designated as safety issue: Yes ]
    Procedural success is defined as obtainment of ≤30% residual stenosis by visual estimate (with or without stenting)

  • Clinical Success [ Time Frame: Day 1 ] [ Designated as safety issue: Yes ]
    Clinical success is defined as procedural success without procedural complications (death, stroke, major target limb amputation, thrombosis of the target lesion, or target vessel revascularization (TVR)) prior to discharge.

  • Days of Hospitalization Due to the Index Lesion [ Time Frame: 12 month ] [ Designated as safety issue: No ]
    Days of hospitalization from procedure through 12 month.

Enrollment: 331
Study Start Date: September 2010
Estimated Study Completion Date: June 2016
Primary Completion Date: February 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Drug-Coated Balloon (DCB)
IN.PACT Admiral: Balloon Angioplasty
Device: Drug-Coated Balloon (DCB)
balloon dilatation and provisional stenting with IN.PACT DCB
Active Comparator: Standard PTA
Standard Percutaneous Transluminal Angioplasty (PTA) Balloon: Balloon Angioplasty
Device: PTA Balloon: Balloon Angioplasty
balloon dilatation and provisional stenting with standard non-coated PTA balloon

Detailed Description:

The efficacy of the IN.PACT Admiral balloon will be evaluated by assessing the primary patency rate of the treated arteries in the thighs of all patients included in the Study. Primary patency is a measure of the durability up to 1 year of the free lumen in the artery as restored during the procedure and is based on:

  • the need for re-dilatation of the previously treated vessel segment
  • an ultrasound examination The safety of the IN.PACT Admiral will be assessed by evaluating the incidence of deaths, amputations and re-dilatation of the pre-treated arteries in all patients included in the Study.

The IN.PACT SFA Trial enrolled in 2 phases: IN.PACT SFA I and IN.PACT SFA II. The 150-patient IN.PACT SFA I phase is intended to support the second phase IN.PACT SFA II IDE trial with congruent design and protocol. Aggregate data from the two phases is intended to provide statistical power for the 12-month primary safety and effectiveness endpoints.


Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

General Inclusion Criteria:

  • Age ≥18 years and ≤85 years
  • Patient or patient's legal representative is informed of the nature of the study, agrees to participate and has signed an EC approved consent form

Angiographic Inclusion Criteria:

- Target vessel is the superficial femoral artery and/or proximal popliteal artery (above the knee)

General Exclusion Criteria:

  • Patient unwilling or unlikely to comply with follow-up schedule
  • Stroke or STEMI within 3 months prior enrolment

Angiographic Exclusion Criteria:

- Acute or sub-acute thrombus in the target vessel

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01175850

Klinikum Rosenheim Institut für Diagnostische und Interventionelle Radiologie
Rosenheim, Pettenkoferstr, Germany, 83022
Sponsors and Collaborators
Medtronic Endovascular
Principal Investigator: Gunnar Tepe, Prof Dr. Med Klinikum Rosenheim
  More Information

No publications provided by Medtronic Endovascular

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Medtronic Endovascular
ClinicalTrials.gov Identifier: NCT01175850     History of Changes
Other Study ID Numbers: P990
Study First Received: August 3, 2010
Results First Received: February 24, 2015
Last Updated: September 3, 2015
Health Authority: Italy: Ministry of Health

Additional relevant MeSH terms:
Peripheral Arterial Disease
Peripheral Vascular Diseases
Arterial Occlusive Diseases
Cardiovascular Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on November 30, 2015